(NASDAQ: KROS) Keros Therapeutics's forecast annual revenue growth rate of -51.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Keros Therapeutics's revenue in 2025 is $232,844,000.On average, 6 Wall Street analysts forecast KROS's revenue for 2025 to be $9,569,194,615, with the lowest KROS revenue forecast at $8,935,391,080, and the highest KROS revenue forecast at $10,129,890,406. On average, 2 Wall Street analysts forecast KROS's revenue for 2026 to be $1,076,308,471, with the lowest KROS revenue forecast at $528,000,382, and the highest KROS revenue forecast at $1,624,616,560.
In 2027, KROS is forecast to generate $1,077,770,626 in revenue, with the lowest revenue forecast at $108,849,310 and the highest revenue forecast at $2,030,770,700.